LEGN Legend Biotech Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LEGN

Price (delayed)

$45.46

Market cap

$8.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.94

Enterprise value

$7.29B

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated ...

Highlights
The gross profit has soared by 173% YoY and by 43% from the previous quarter
The revenue has surged by 144% year-on-year and by 22% since the previous quarter
The quick ratio has soared by 89% YoY but it has contracted by 20% from the previous quarter
The equity has soared by 68% YoY but it is down by 7% from the previous quarter
The company's net income fell by 16% YoY
Legend Biotech's debt has increased by 16% YoY and by 2.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of LEGN
Market
Shares outstanding
181.91M
Market cap
$8.27B
Enterprise value
$7.29B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.6
Price to sales (P/S)
28.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.57
Earnings
Revenue
$285.14M
EBIT
-$498.32M
EBITDA
-$477.87M
Free cash flow
-$460.39M
Per share
EPS
-$2.94
Free cash flow per share
-$2.61
Book value per share
$6.88
Revenue per share
$1.62
TBVPS
$10.48
Balance sheet
Total assets
$1.85B
Total liabilities
$597.24M
Debt
$328.67M
Equity
$1.25B
Working capital
$1.28B
Liquidity
Debt to equity
0.26
Current ratio
6.92
Quick ratio
6.51
Net debt/EBITDA
2.05
Margins
EBITDA margin
-167.6%
Gross margin
49.4%
Net margin
-181.8%
Operating margin
-134.7%
Efficiency
Return on assets
-30.4%
Return on equity
-44.6%
Return on invested capital
-73.1%
Return on capital employed
-30.5%
Return on sales
-174.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LEGN stock price

How has the Legend Biotech stock price performed over time
Intraday
-1.02%
1 week
0.35%
1 month
-19.37%
1 year
-31.45%
YTD
-24.45%
QTD
-18.95%

Financial performance

How have Legend Biotech's revenue and profit performed over time
Revenue
$285.14M
Gross profit
$140.93M
Operating income
-$384.09M
Net income
-$518.25M
Gross margin
49.4%
Net margin
-181.8%
The gross profit has soared by 173% YoY and by 43% from the previous quarter
The revenue has surged by 144% year-on-year and by 22% since the previous quarter
The operating margin has soared by 65% YoY and by 20% QoQ
Legend Biotech's net margin has surged by 52% YoY and by 17% QoQ

Growth

What is Legend Biotech's growth rate over time

Valuation

What is Legend Biotech stock price valuation
P/E
N/A
P/B
6.6
P/S
28.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.57
The EPS has declined by 5% year-on-year
The equity has soared by 68% YoY but it is down by 7% from the previous quarter
The stock's price to book (P/B) is 30% less than its last 4 quarters average of 9.5
The revenue has surged by 144% year-on-year and by 22% since the previous quarter
The P/S is 52% less than the last 4 quarters average of 58.9

Efficiency

How efficient is Legend Biotech business performance
The return on sales has surged by 53% year-on-year and by 16% since the previous quarter
LEGN's return on invested capital is up by 47% year-on-year and by 4.4% since the previous quarter
The company's return on equity rose by 25% YoY and by 9% QoQ
LEGN's return on assets is up by 16% year-on-year and by 6% since the previous quarter

Dividends

What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEGN.

Financial health

How did Legend Biotech financials performed over time
The quick ratio has soared by 89% YoY but it has contracted by 20% from the previous quarter
Legend Biotech's current ratio has surged by 88% YoY but it has decreased by 20% QoQ
Legend Biotech's debt is 74% lower than its equity
The equity has soared by 68% YoY but it is down by 7% from the previous quarter
The debt to equity has contracted by 32% YoY but it has grown by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.